First Time Ever, Cuban Lung Cancer Vaccine Being Tested In U.S. Trial
Follow CBSMIAMI.COM: Facebook | Twitter
BUFFALO, N.Y. (CBSMiami/AP) — A New York cancer research and treatment center has received approval from the Food and Drug Administration to conduct a clinical trial of an innovative lung cancer vaccine developed in Cuba.
Democratic Gov. Andrew Cuomo joined officials with Roswell Park Cancer Institute Wednesday to announce the trial, which is the first of its kind since the recent thaw in relations between the U.S. and Cuba.
Called CIMAvax-EGF, the treatment is an immunotherapy developed by Havana's Center of Molecular Immunology. The trial will involve 60 to 90 patients and is expected to begin next month.
Roswell Park President Candace Johnson says the trial is the result of collaboration between officials in New York and Cuba that started when Cuomo led a trade delegation to Havana in 2015.
Clinical trials for #CIMAvax are expected to begin within 30 days. Please visit our website for updates: https://t.co/vK81I89Qv0 #lungcancer pic.twitter.com/328obpY19G
— Roswell Park (@RoswellPark) October 26, 2016
"It's the first time in the modern era that a Cuban and an American institution have been allowed to come together," she said.
Jose Ramon Cabanas Rodriguez, Cuban ambassador to the U.S., wrote to Cuomo to congratulate him on the partnership. He wrote that it represented "not only a contribution to the improvement of the health of the peoples from our countries but to the health of all the peoples in the region and the world as well."
The clinical trial validates efforts to lure top-tier research to upstate New York, Cuomo said.
"Cuba could have gone anywhere in the United States," he said. "They could have gone to Johns Hopkins. They could have gone to Memorial Sloan Kettering. ... Where did they choose? The best place in the United States, Roswell Park."
(TM and © Copyright 2016 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2016 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.)